EGFR and lung carcinoma: Compared to the TCGA data, the Nanjing Lung Cancer Cohort (NJLCC) (4) and CHOICE cohort (24) of Chinese patients revealed higher rates of EGFR and RB1 mutations, and lower rates of KRAS, BRAF, and STK11 mutations, in adenocarcinoma patients.